nanoRETE, Inc. provides real-time detection of pathogens using customized nanoparticle biosensors. The company has developed a platform that has the ability to test for numerous pathogens (anthrax, E. Coli, salmonella, tuberculosis, etc.) using a simple-to-use handheld device which generates screening results in about one hour.
A nanotechnology-based platform for single molecule identification and digital quantification. The NanoString™ system uniquely barcodes individual target molecules, scans them, and delivers a literal inventory of target molecules in the biological sample.
An early stage therapeutic drug company, NanoVector Inc. is commercializing a patent pending nanoparticle drug delivery system developed at North Carolina State University. The NanoVector nanoparticle is a plant virus. Central to our technology, this virus, which has evolved over millions of years, has several inherent characteristics essential for a successful nanoparticle delivery system and superior to any designed and engineered by humans.
Novavax is focused on creating novel, highly potent recombinant vaccines produced via cell culture. The company has developed three proprietary technology platforms: Virus-Like Particles, NovasomeŽ paucilamellar vesicles and Micellar Nanoparticles.
OmegaGenesis, Inc. is a biotechnology company that discovers and produces nano-scale materials that work on the cellular and sub-cellular level to promote or inhibit angiogenesis, the growth of new blood vessels.
Combining recent advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, the company has created a powerful technology platform called single molecule, real-time, or SMRT, technology. SMRT technology enables real-time analysis of biomolecules with single molecule resolution, which has the potential to transform our understanding of biological systems by providing a window into these systems that has not previously been open for scientific study.
Parabon NanoLabs designs and develops a new class of therapeutics and other products made possible by proprietary technology for precisely directing the self-assembly of designer macromolecules that are functionalized with molecular subcomponents (e.g., enzymes, metals or pharmaceuticals).
Particle Sciences is an integrated provider of both standard and nanotechnology approaches to drug development and delivery. The company originally pioneered use of encapsulated ingredients and nanoparticles for sunscreens and personal care. In 1999 the company licensed a portion of its nanotechnology portfolio to BASF and focused its efforts on providing services to Life Sciences companies. Now, through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution designed to minimize the time and risk between discovery and the clinic.
PDS Biotechnology Corporation is a biopharmaceutical company applying the company's platform Versamune nanotechnology to a new class of safe, simple, potent and targeted immunotherapies for the treatment of cancer and infectious diseases.